[go: up one dir, main page]

NZ576563A - Alphavirus and alphavirus replicon particle formulations and methods - Google Patents

Alphavirus and alphavirus replicon particle formulations and methods

Info

Publication number
NZ576563A
NZ576563A NZ57656307A NZ57656307A NZ576563A NZ 576563 A NZ576563 A NZ 576563A NZ 57656307 A NZ57656307 A NZ 57656307A NZ 57656307 A NZ57656307 A NZ 57656307A NZ 576563 A NZ576563 A NZ 576563A
Authority
NZ
New Zealand
Prior art keywords
alphavirus
methods
particle formulations
replicon particle
sugar
Prior art date
Application number
NZ57656307A
Inventor
Roberto Depaz
Todd L Talarico
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of NZ576563A publication Critical patent/NZ576563A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided is a dried composition with rehydration and storage stability comprising (1) alphaviruses or alphavirus replicon particles, (2) a salt, (3) a surfactant, and (4) a hydrogen-bonding sugar, sugar alcohol or other polyol, wherein the hydrogen-bonding sugar, sugar alcohol or other polyol is selected from trehalose, sucrose, raffinose, maltodextrin, fructose, glycerol, sorbitol, inositol and mannose, and (5) a plasticizer. The alphavirus can be Venezuelan Equine Encephalitis Virus (VEE).
NZ57656307A 2006-11-03 2007-11-02 Alphavirus and alphavirus replicon particle formulations and methods NZ576563A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86436606P 2006-11-03 2006-11-03
PCT/US2007/083537 WO2008058035A1 (en) 2006-11-03 2007-11-02 Alphavirus and alphavirus replicon particle formulations and methods

Publications (1)

Publication Number Publication Date
NZ576563A true NZ576563A (en) 2012-09-28

Family

ID=39110550

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ57656307A NZ576563A (en) 2006-11-03 2007-11-02 Alphavirus and alphavirus replicon particle formulations and methods

Country Status (10)

Country Link
US (2) US20090047255A1 (en)
EP (1) EP2099485B1 (en)
AU (1) AU2007317347B2 (en)
CA (1) CA2668417A1 (en)
DK (1) DK2099485T3 (en)
ES (1) ES2673823T3 (en)
IL (1) IL198364A (en)
NZ (1) NZ576563A (en)
WO (1) WO2008058035A1 (en)
ZA (1) ZA200903791B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US20120128714A1 (en) 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
ES2543795T3 (en) * 2010-03-31 2015-08-21 Stabilitech Ltd. Stabilization of viral particles
ES2708989T3 (en) 2010-03-31 2019-04-12 Stabilitech Biopharma Ltd Method of preservation of alum adjuvants and alum-enhanced vaccines
WO2011121301A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
EA201390810A1 (en) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. LIQUID VIRAL COMPOSITIONS
KR102023207B1 (en) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 Lyophilized viral formulations
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
JP6494527B2 (en) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション Protein antigens that provide protection from pneumococcal colonization and / or disease
CA2903711A1 (en) * 2013-03-14 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
KR101398764B1 (en) 2013-08-29 2014-05-27 강릉원주대학교산학협력단 Device for detecting analytes by moving the particle and method using the same
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
EP3928800A3 (en) 2015-05-20 2022-03-23 CureVac AG Dry powder composition comprising long-chain rna
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
JP7412002B2 (en) 2017-12-20 2024-01-12 ブイエルピー・セラピューティクス・インコーポレイテッド alphavirus replicon particle
CN116134131A (en) 2019-12-31 2023-05-16 伊利克斯根治疗公司 Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
CN115552009A (en) * 2020-04-30 2022-12-30 Vlp治疗公司 Cytokine immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (en) * 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
JP2001500738A (en) * 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000039318A1 (en) * 1998-12-31 2000-07-06 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
DK1150712T3 (en) * 1999-02-05 2009-02-02 Merck & Co Inc Human papillomavirus vaccine formulations
DE60027768T2 (en) 1999-08-17 2007-04-05 Purdue Research Foundation, West Lafayette TREATMENT OF METASTATIC DISEASE
OA12312A (en) * 1999-08-17 2006-05-12 Smithkline Beecham Biolog Vaccine.
DE60135983D1 (en) * 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic PROCESS FOR CLEANING ALPHAVIRAL REPLICANT PARTICLES
DE60233061D1 (en) * 2001-09-06 2009-09-03 Alphavax Inc ALPHAVIRUS REPLICON VECTOR SYSTEMS
WO2003049764A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
JP4583762B2 (en) * 2002-02-27 2010-11-17 イミュネックス・コーポレーション Polypeptide preparation
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
ES2890023T3 (en) * 2002-12-13 2022-01-17 Alphavax Inc Alphavirus particles and preparation methods
NZ542353A (en) 2003-03-20 2008-07-31 Alphavax Inc Improved alphavirus replicons and helper constructs
PT1751289E (en) * 2004-05-18 2009-03-31 Alphavax Inc Tc-83-derived alphavirus vectors, particles and methods
BRPI0511764B8 (en) * 2004-06-01 2021-05-25 Avigen Inc method of preventing aggregation of recombinant adeno-associated virus (raav) virions in a purified preparation of raav virions
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods

Also Published As

Publication number Publication date
DK2099485T3 (en) 2018-05-22
IL198364A (en) 2017-11-30
EP2099485B1 (en) 2018-03-21
US20090047255A1 (en) 2009-02-19
EP2099485A1 (en) 2009-09-16
ZA200903791B (en) 2010-03-31
US20110182941A1 (en) 2011-07-28
WO2008058035A1 (en) 2008-05-15
ES2673823T3 (en) 2018-06-25
US9187729B2 (en) 2015-11-17
CA2668417A1 (en) 2008-05-15
AU2007317347B2 (en) 2014-02-06
IL198364A0 (en) 2011-08-01
AU2007317347A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
NZ576563A (en) Alphavirus and alphavirus replicon particle formulations and methods
MXPA06013124A (en) Tc-83-derived alphavirus vectors, particles and methods.
WO2006079083A3 (en) Laser material micromachining with green femtosecond pulses
PH12014502092B1 (en) Stabilizing composition for biological materials
WO2014131584A3 (en) Aqueous formulations, their manufacture, and their use in hard surface cleaning
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EP1847277A4 (en) Sheet-shaped composition utilizing amnion and method of preparing the same
CO6120154A1 (en) OIL FORMULATIONS
WO2012166478A3 (en) Soluble solid hair coloring article
EP4219731A3 (en) Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
WO2013139482A8 (en) Surgical implant
WO2012166477A3 (en) Soluble solid hair coloring article
WO2009131604A3 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
WO2010022342A3 (en) Combination dry erase board/projection screen
CL2017001309A1 (en) Products composed of biogenic silica opaline / expanded perlite
MXPA05012542A (en) Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens.
WO2009080699A3 (en) Peg-interferon-beta formulations
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
WO2006017206A3 (en) Flavivirus vaccine
CN205006485U (en) Antiskid dish and tray thereof
EP3535398A4 (en) Dengue virus-like particle, antibody against dengue virus, and composition comprising the same
IL278011B2 (en) Pharmaceutical dry powder composition for inhalation containing thyroid hormone
RU2019119845A (en) METHOD FOR OBTAINING COATED DOSE FORM
Anping Research progresses of rural regional-system degradation
CN205640053U (en) Three proofings heat preservation quilt

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ALPHAVAX, INC., US

Free format text: OLD OWNER(S): ALPHAVAX, INC.; ROBERTO A DEPAZ; TODD L TALARICO

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO APPLICANT CHAIN OF TITLE (71)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 NOV 2014 BY AJ PARK

Effective date: 20130419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 02 NOV 2027 BY AJ PARK

Effective date: 20140826

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 NOV 2017 BY AJ PARK

Effective date: 20140826

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 NOV 2020 BY AJ PARK

Effective date: 20140826